Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Genomics of Thyroid Cancer
FY 2009-10
Summary
An estimated 4% to 7% of the population will develop a clinically significant thyroid nodule during their lifetime. In many cases, preoperative diagnoses by needle biopsy are inconclusive and so a large proportion of individuals undergo thyroidectomy as a diagnostic procedure for cancer. Several studies have evaluated the molecular phenotype of thyroid cancer and benign thyroid lesions to identify molecular markers that allow for accurate diagnosis. Panels composed of both novel and established markers have been characterized by these studies. However, the molecular mechanisms underlying thyroid cancers are still poorly understood; hence the need for a more comprehensive analysis.
Most of the mutations in DNA sequence can be identified using massively parallel next-generation sequencing technologies. Several individuals' genomes as well as tumor samples have been sequenced for a small fraction of the cost of sequencing the first human genome. However, the cost of whole-genome sequencing is still too high. Sequencing only the transcriptome of tumor specimens can greatly reduce this cost while identifying the majority of the mutations, located in the coding regions. I propose to undertake a complete sequence analysis of the transcriptomes of thyroid cancers in order to characterize the underlying molecular mechanism of this disease. Utilizing next-generation sequencing technologies, I will shotgun sequence the transcribed regions of the dissected thyroid tumors as well as the matched normal tissue. This analysis will provide information not only on the quantitative expression of genes within the tumor but also mutations that have accrued within it during oncogenesis. Inter-se comparison between the tumors will allow commonly mutated genes in thyroid cancer to be identified. These mutations will help in determining the underlying mechanisms of the disease, identifying proteins and pathways for therapeutic intervention and defining molecular subtypes of the disease.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
201584
Name
Kasaian Katayoon
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Genomics of Thyroid Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bioinformatic Analysis; Biostatistics; Detection Of Novel Transcript Isoforms; Detection Of Structural Variations; Gene Fusion Detection; Genomics; Molecular Genetics; Next Generation Sequencing; Software Engineering; Whole Transcriptome Analysis
Abstract
An estimated 4% to 7% of the population will develop a clinically significant thyroid nodule during their lifetime. In many cases, preoperative diagnoses by needle biopsy are inconclusive and so a large proportion of individuals undergo thyroidectomy as a diagnostic procedure for cancer. Several studies have evaluated the molecular phenotype of thyroid cancer and benign thyroid lesions to identify molecular markers that allow for accurate diagnosis. Panels composed of both novel and established markers have been characterized by these studies. However, the molecular mechanisms underlying thyroid cancers are still poorly understood; hence the need for a more comprehensive analysis.
Most of the mutations in DNA sequence can be identified using massively parallel next-generation sequencing technologies. Several individuals' genomes as well as tumor samples have been sequenced for a small fraction of the cost of sequencing the first human genome. However, the cost of whole-genome sequencing is still too high. Sequencing only the transcriptome of tumor specimens can greatly reduce this cost while identifying the majority of the mutations, located in the coding regions. I propose to undertake a complete sequence analysis of the transcriptomes of thyroid cancers in order to characterize the underlying molecular mechanism of this disease. Utilizing next-generation sequencing technologies, I will shotgun sequence the transcribed regions of the dissected thyroid tumors as well as the matched normal tissue. This analysis will provide information not only on the quantitative expression of genes within the tumor but also mutations that have accrued within it during oncogenesis. Inter-se comparison between the tumors will allow commonly mutated genes in thyroid cancer to be identified. These mutations will help in determining the underlying mechanisms of the disease, identifying proteins and pathways for therapeutic intervention and defining molecular subtypes of the disease.
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kasaian, Katayoon
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~